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Background: Patient preferences derived from an assessment of values can help inform the design of screening
programs, but how best to do so, and whether such preferences differ cross-nationally, has not been well-examined.
The objective of this study was to compare the values and preferences of Australian and US men for PSA (prostate
specific antigen) screening.
Methods: We used an internet based survey of men aged 50–75 with no personal or family history of prostate cancer
recruited from on-line panels of a survey research organization in the US and Australia. Participants viewed information
on prostate cancer and prostate cancer screening with PSA testing then completed a values clarification task that
included information on 4 key attributes: chance of 1) being diagnosed with prostate cancer, 2) dying from prostate
cancer, 3) requiring a biopsy as a result of screening, and 4) developing impotence or incontinence as a result of
screening. The outcome measures were self reported most important attribute, unlabelled screening test choice, and
labelled screening intent, assessed on post-task questionnaires.
Results: We enrolled 911 participants (US:456; AU:455), mean age was 59.7; 88.0% were white; 36.4% had completed at
least a Bachelors’ degree; 42.0% reported a PSA test in the past 12 months. Australian men were more likely to be
white and to have had recent screening. For both US and Australian men, the most important attribute was the
chance of dying from prostate cancer. Unlabelled post-task preference for the PSA screening-like option was greater
for Australian (39.1%) compared to US (26.3%) participants (adjusted OR 1.68 (1.28-2.22)). Labelled intent for screening
was high for both countries: US:73.7%, AUS:78.0% (p = 0.308).
Conclusions: There was high intent for PSA screening in both US and Australian men; fewer men in each country
chose the PSA-like option on the unlabelled question. Australian men were somewhat more likely to prefer PSA
screening. Men in both countries did not view the increased risk of diagnosis as a negative aspect, suggesting more
work needs to be done on communicating the concept of overdiagnosis to men facing a PSA screening decision.
Trial registration: This trial was registered at ClinicalTrials.gov (NCT01558583).Background
Whether to undergo prostate-specific antigen (PSA)
screening is a difficult decision for middle-aged men.
Prostate cancer is common, and causes over 29000 deaths
per year in the US and approximately 3000 per year in
Australia [1,2]. However, PSA screening, at best, seems to
produce only a small reduction in prostate cancer mortal-
ity and has considerable downsides [3,4]. These downsides
include increases in the number of prostate biopsies* Correspondence: kirsten.howard@sydney.edu.au
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reproduction in any medium, provided the or(which can be painful and have a risk of causing infection),
as a result of abnormal PSA screen results; overdiagnosis,
(i.e. the detection of cancers that would never become
clinically apparent or problematic); and increased treat-
ment and treatment-related adverse effects (impotence
and incontinence) [3-5].
Because the number of men who benefit from screening
is small and the downsides common, guideline-making or-
ganisations often recommend a shared decision making
approach incorporating an individual’s own values and
preferences: “men thinking about prostate cancer screen-
ing should make informed decisions based on availablel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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views on the benefits and side effects of screening and
treatment” [6] (American Cancer Society); “…whether or
not to be tested for prostate cancer is a matter of individ-
ual choice” [7] (Cancer Council of Australia).
Despite these recommendations, surveys suggest that
few men are adequately informed about the benefits and
downsides of screening [8,9] and that testing rates are
high in many western countries, including the US and
Australia [10-12].
The objective of our study was to compare how Australian
and US men value different attributes of PSA screening
and whether such values affect their preferences for
whether to be tested or not.
Methods
Overview
We surveyed male members of on-line panels in the US
and Australia. Details of methods have been previously
reported elsewhere [13]; a brief summary of methods is
provided below. This paper focuses on cross country
comparisons of values and preferences. The results of the
comparison of different values clarification methods
(VCM) have been previously published [13].
Participant eligibility and recruitment
We used the online panels maintained by an international
research firm Survey Sampling International (SSI) to re-
cruit a target of 900 men (450 US, 450 Australia). Partici-
pants aged 50–75 who had no personal or family history
of prostate cancer were targeted. Prior testing history was
assessed but not used to determine eligibility. Those with
visual limitations or inability to understand English were
excluded.
Study flow
The entire study was performed online. After eligibility
was determined and consent obtained, participants re-
ceived basic information about prostate cancer and PSA
screening, completed demographic questions, and were
then randomized by SSI on a 1:1:1 basis, stratified by coun-
try, to one of three values clarification methods (VCM): 1)
an implicit values clarification method (a balance sheet of
key test attributes); 2) a rating and ranking task; or 3) a
discrete choice experiment (DCE), followed by post-task
questions.
Selection of attributes and levels
For all values clarification methods, we described the PSA
screening decision (whether or not to be screened) in
terms of four key attributes: 1) chance of being diagnosed
with prostate cancer, 2) chance of dying from prostate
cancer, 3) chance of requiring a biopsy as a result of
screening, and 4) chance of developing impotence orincontinence as a result of screening. The attributes and
the range of levels of the attributes included were drawn
from the literature and our own previous work [3,5].
Study outcomes
Our three main outcomes of interest were 1) the
participant-reported most important attribute (“Which
ONE feature of prostate cancer screening is most import-
ant to you?” chosen from the four attributes above), 2) the
post-task testing preference, based on a question that in-
cluded two unlabelled options described in terms of the
key decision attributes and designed to mimic screening
or no screening options - we call this “unlabelled test pref-
erence” (Figure 1); and 3) a single post-task question
about intent to be screened with PSA, based on a Likert
scale (from strongly disagree to strongly agree, with agree
and strongly agree considered as positive intent to be
screened) - we refer to this as the “labelled test
preference”.
Analyses
We performed initial descriptive analyses of all variables
with means and proportions. We used chi-square and
ANOVA for bivariate analyses across the two country
groups and calculated unadjusted odds ratios (OR) and
95% confidence intervals of OR. Because of baseline demo-
graphic differences between the US and Australian men,
we also performed multivariate analyses using logistic re-
gression, and adjusted for potential confounders, including
age, race, education, income, and prior PSA testing.
We also assessed the relationship between the participant-
reported most important attribute and unlabelled test
preference. A priori we expected that if mortality benefit
is the most important attribute, then unlabelled test pref-
erence should favour the screening-like test option, and
more men choosing the screening-like option would also
choose chance of death as the most important attribute.
Similarly, if potential harms such as impotence/incontin-
ence, or the chance of diagnosis were most important,
then we might expect men to prefer the unlabelled test
option that described no screening.
Ethical considerations
This study was approved by the University of North
Carolina - Chapel Hill Institutional Review Board on
April 28, 2011 (Study number 11–0861) and is registered
through ClinicalTrials.gov (NCT01558583).
Results
We screened 2336 individuals from October, 12 – 27,
2011. Of these, 595 were ineligible, 705 declined partici-
pation before being randomised and 1036 were random-
ized. Of these 1036, 911 (87.9%) completed the full
survey. Participant characteristics are shown in Table 1.
Figure 1 Unlabelled test preference question.
Table 1 characteristics of participants overall (n = 911)
and by country
Overall United States Australia p-value
(n = 911) (n = 456) (n = 455)
Mean age (SD) 59.8 (5.6) 59.7(5.5) 59.8 (5.7) p = 0.730
Ethnicity 88.0% 82.5% 93.6% p < 0.0001
(% White)
Education p < 0.0001
Less than high school
graduate
7.2% 2.0% 12.5%
High school graduate
or some college
56.3% 51.1% 61.5%
College graduate 36.4% 46.9% 25.9%
Income p = 0.049
<$30,000 24.0% 23.9% 24.2%
$30,000-59,999 30.4% 32.2% 28.6%
> = $60,000 35.9% 36.8% 34.9%
Prefer Not to Answer 9.7% 7.0% 12.3%
Employment p = 0.002
Employed 36.4% 36.8% 36.0%
Retired 39.3% 37.1% 41.5%
Other 24.3% 26.1% 22.5%
PSA testing p = 0.103
within past year 42.0% 38.6% 45.5%
> 1 year ago 20.9% 21.7% 20.0%
Never/Don’t know 37.1% 39.7% 34.5%
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try groups in the proportion of white participants, edu-
cation level and the proportion reporting PSA testing
within the past 12 months.
Main outcomes
The participant-reported most important attribute from
the single post-task questionnaire indicated similar pro-
portions of US and Australian respondents choosing spe-
cific test attributes as the most important (Table 2).
Australian men were no more likely than US men to
choose mortality as the most important attribute: 41.8% vs
39.7% (unadjusted OR 1.05 (0.89-1.23); adjusted OR 1.14
(0.88 - 1.49)). Australian men were slightly less likely to
choose impotence/incontinence as the most important at-
tribute (15.4% vs 21.3%, p = 0.022, unadjusted OR 0.67
(0.48 - 0.94)). This effect was slightly attenuated after ad-
justment for confounders (adjusted OR 0.72 (0.51 - 1.03)).
Unlabelled test preference
In terms of unlabelled test preference, Australian men
were significantly more likely (39.1%) to prefer the PSA-
like option (as opposed to the no screening option), com-
pared to US men (26.3%), p < 0.0001, unadjusted OR 1.46
(1.34 – 1.56). This difference remained after adjustment
for potential confounders (adjusted OR 1.68 (1.28 – 2.22).
Does the most important attribute influence unlabelled
test preference?
We assessed the relationship between the most important
attribute and unlabelled test preference. Overall, the rela-
tionship between most important attribute and unlabelled
Table 2 Most important attribute from post-task
questionnaire
US
(n = 456)
AUS
(n = 455)
p-value
(pairwise)
Chance of being diagnosed
over 10 years
27.2% 32.3% 0.091
Chance of dying over 10 years 39.7% 41.8% 0.526
Chance of needing a biopsy
from screening over 10 years
11.8% 10.5% 0.536
Chance of impotence/incontinence
over 10 years
21.3% 15.4% 0.022
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of men choosing the chance of dying as most important
was lower for those choosing the no screening-like option,
and the proportion of men choosing impotence/incontin-
ence as most important was higher for those choosing the
no screening-like option (Table 3).
In US men, the proportion choosing death as most im-
portant was lower (36%) for those choosing the no screen-
ing like-option compared with men who chose the
screening-like option (51%), as might be expected; simi-
larly, the proportion choosing incontinence/impotence as
most important was higher (24% vs. 13%, respectively);
and the proportion choosing chance of diagnosis or biopsy
as most important did not differ based on unlabelled test-
ing preference (overall chi2 with 3 df = 10.917, p = 0.012).
In Australian men, we observed a similar, but attenu-
ated, pattern for the choice of mortality reduction, and a
similar pattern for the choice of impotence or incontin-
ence. Australian men who preferred the screening-like
option were, however, more likely to choose chance of
diagnosis as the most important attribute compared to
those who preferred the no screening-like option. As in
US men, there were no differences by testing preference
in the proportion choosing chance of biopsy as most im-
portant (overall chi2 with 3df = 13.854, p = 0.003).Table 3 Relationship between most important attribute and u
Attribute Overall (n = 911)
Unlabelled test preference
No screening
like option
(n = 613)
Screening-lik
option
(n = 298)
N % N %
Chance of being diagnosed over
10 years
172 28.1% 99 33.2%
Chance of dying over 10 years 231 37.7% 140 47.0%
Chance of needing a biopsy from screening
over 10 years
73 11.9% 29 9.7%
Chance of impotence/incontinence over
10 years
137 22.3% 30 10.1%Screening intent
Labelled screening intent was high amongst participants
from both countries (mean intent score: Australia 4.04;
US 3.95; p = 0.110). The proportion of participants who
agreed or strongly agreed that they intended to have PSA
testing when labelled as such was high and did not differ
between groups (Australia, 78.6%; US 73.7% p = 0.130)
(Table 4).
Discussion
We found that Australian and US men had similar prefer-
ence structures with respect to attributes of PSA screen-
ing. When faced with an unlabelled question, about a
third of men expressed a preference for the PSA-like op-
tion. Australian men were more likely to prefer the PSA-
like option (over the no screening option) compared to
US men. However, labelled intent to have PSA testing was
high amongst both US and Australian men, with approxi-
mately three quarters of men indicating that they intended
to be screened.
The finding that PSA screening was favoured by a
greater proportion of Australian than US men on the un-
labelled test preference question was unexpected: we had
anticipated similar results between countries. Both coun-
tries have relatively high rates of screening on national
surveys, [12,14] and this finding may have occurred by
chance. However, it is also possible that the recent
USPSTF guidelines [15], which were published in draft
form in October 2011 (near the time of our data collec-
tion), may have had a (larger) effect on US men’s prefer-
ences. It is possible that doctors’ practices for discussing
PSA testing may vary across countries, and that doctors
in the US are less likely to discuss PSA testing than
Australian doctors, although indirect evidence does not
suggest this is the case [8,16].
Our findings have a number of implications. First, they
suggest that the PSA label has a strong effect in each
country: a large proportion of both US and Australiannlabelled test preference
US (n = 456) AUS (n = 455)
Unlabelled test preference Unlabelled test preference
e No screening
like option
(n = 336)
Screening-like
option
(n = 120)
No screening-like
option
(n = 277)
Screening-like
option
(n = 178)
N % N % N % N %
92 27.4% 32 26.7% 80 28.9% 67 37.6%
120 35.7% 61 50.8% 111 40.1% 79 44.4%
43 12.8% 11 9.2% 30 10.8% 18 10.1%
81 24.1% 16 13.3% 56 20.2% 14 7.9%
Table 4 Intent to be screened by country
Overall
(n = 911)
US
(n = 456)
AUS
(n = 455)
p-value
N % N % N %
Strongly Disagree [1] 19 2.1% 12 2.6% 7 1.4%
0.441
Disagree 33 3.6% 20 4.4% 13 2.9%
Neither Agree nor
Disagree
168 18.4% 88 19.3% 80 17.6%
Agree 399 43.8% 193 42.3% 206 45.3%
Strongly Agree [5] 292 32.1% 143 31.4% 149 32.7%
Mean Intent (SD) 4.00 (0.91) 3.95 (0.96) 4.04 (0.87) 0.110
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ence for the “no PSA” option in the unlabelled question.
The observed labelling effect suggests that men may be
unaware of the true characteristics of PSA testing or that
there are other attributes of benefit of the test that are not
captured in our study.
Indirect evidence suggests that men did not under-
stand or appreciate that the effect of PSA on increasing
the chance of prostate cancer diagnosis in and of itself
should not always be considered a benefit of screening,
because of overdiagnosis. Considering the chance of
diagnosis to be the most important attribute was associ-
ated with choosing the PSA-like option in the unlabelled
question, despite the fact that screening increases risk.
The challenges in communicating the concept of overdi-
agnosis are considerable, and require increased attention
in the future, both for this question and other screening
issues [17].
Our study has some methodological limitations that
must be considered. First, it was conducted among an on-
line panel. Whether the effects we observed would differ
in men making the screening decision in a clinical setting
is unclear. We attempted to bolster the salience of the
question by enrolling men of screening age and asked
them to answer as if they were actually deciding about
whether to be tested, but we did not measure actual
screening behaviour. Future studies should do so. Given
the online panel recruitment, our participants may not be
completely representative of the population of US and
Australian men in this age group; however they were
broadly comparable on factors such as education, employ-
ment status and prior test experience. Whether under-
represented populations would have different preferences
is unknown. We did not present participants with a full
decision aid and we did not assess knowledge specifically,
making it difficult to sort out effects of understanding vs.
those related to values and preferences. That said, our sur-
vey instrument contained sufficient information to frame
the decision appropriately.
Our findings can be used to enhance the shared deci-
sion making process, with more attention given toensuring that men understand the key features of the
PSA test, and recognise the potential downside of an in-
creased risk of diagnosis. Future studies should examine
the effect of feeding back the results of values clarification
methods, particularly when they stand in contrast to men’s
stated preferences for whether or not to be tested. Discus-
sion of values and test preference may help patients arrive
at an informed, value-concordant decision.
Conclusions
We found that Australian and US men had high intent for
PSA screening but that fewer men in each country chose
the PSA-like option on an unlabelled question. Australian
men were slightly more enthusiastic for screening, even
after adjustment for known confounders. Men in both
countries did not clearly view increased risk of diagnosis
without reduction in mortality (overdiagnosis) as an im-
portant negative aspect of screening, and more work
needs to be done on how best to communicate that con-
cept to men facing the PSA decision and other similar
screening decisions.
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